Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

211 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.
Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, Kato GJ, Ataga KI, Gibbs JS, Castro O, Rosenzweig EB, Sood N, Hsu L, Wilson KC, Telen MJ, Decastro LM, Krishnamurti L, Steinberg MH, Badesch DB, Gladwin MT; American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease. Klings ES, et al. Among authors: barst rj. Am J Respir Crit Care Med. 2014 Mar 15;189(6):727-40. doi: 10.1164/rccm.201401-0065ST. Am J Respir Crit Care Med. 2014. PMID: 24628312 Free PMC article.
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.
Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT; walk-PHaSST Investigators and Patients. Machado RF, et al. Among authors: barst rj. Blood. 2011 Jul 28;118(4):855-64. doi: 10.1182/blood-2010-09-306167. Epub 2011 Apr 28. Blood. 2011. PMID: 21527519 Free PMC article. Clinical Trial.
STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
Langleben D, Brock T, Dixon R, Barst R; STRIDE-1 study group. Langleben D, et al. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S80-4. doi: 10.1097/01.fjc.0000166207.74178.d0. J Cardiovasc Pharmacol. 2004. PMID: 15838366 Clinical Trial.
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L. Galiè N, et al. J Am Coll Cardiol. 2003 Apr 16;41(8):1380-6. doi: 10.1016/s0735-1097(03)00121-9. J Am Coll Cardiol. 2003. PMID: 12706935 Clinical Trial.
New trial designs and potential therapies for pulmonary artery hypertension.
Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. Gomberg-Maitland M, et al. Among authors: barst rj. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D82-91. doi: 10.1016/j.jacc.2013.10.026. J Am Coll Cardiol. 2013. PMID: 24355645 Free PMC article. Review.
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, Gómez-Sánchez MA, Grimminger F, Grünig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA. Hoeper MM, et al. Among authors: barst rj. Circulation. 2013 Mar 12;127(10):1128-38. doi: 10.1161/CIRCULATIONAHA.112.000765. Epub 2013 Feb 12. Circulation. 2013. PMID: 23403476 Clinical Trial.
211 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page